ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements with these filters
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.
API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.
Thyrocare Q1 FY27: Consolidated revenue grew 24.3% YoY to INR 240 Cr, EBITDA margin expanded to 32.2%. Strategy shifts toward specialty diagnostics.
Thyrocare delivered strong Q1 FY27 results with 24% YoY consolidated revenue growth and 34% YoY PAT growth, driven by pathology network expansion and high-value specialty test launches.
Thyrocare Technologies Ltd reported revenue from operations of ₹240 Cr (+24.4% YoY) and net profit of ₹51.3 Cr (+33.9% YoY) for Q1 FY27.
Thyrocare reports strong Q4 FY26 results with 20% consolidated revenue growth and 128% PAT surge, driven by volume growth and core pathology expansion.
Thyrocare reports strong performance for Q4FY26 and FY26 with significant YoY growth in PAT and EBITDA driven by network expansion and operational efficiencies.
Thyrocare reports robust growth for Q4FY26 and FY26, driven by franchise expansion and new specialty launches like Genomics and Allergy testing.
Thyrocare Technologies Ltd reported revenue from operations of ₹223.9 Cr (+19.6% YoY) and net profit of ₹48.7 Cr (+125.5% YoY) for Q4 FY26.